PAR VISION STATEMENT

“Providing patients and customers with uncompromising
quality and value for more than 35 years.”


Partners for Healthcare Excellence
Since 1978, Par Pharmaceutical has been at the forefront of developing, manufacturing, marketing and distributing safe, innovative and cost-effective pharmaceuticals that help improve patient quality of life. Every week in America, more than one million Par prescriptions are dispensed. In return for the trust that is placed in us, we are committed to providing products of uncompromising quality with the highest levels of service. In fulfilling this mission, we deliver value to our customers and the physicians and patients who rely on us. Today, the company’s sales place it among the top 5 largest generic pharmaceutical companies in the United States.

PAR - - People Achieving Results
At Par, our most important resource is the talent and dedication of our nearly 1,600 employees, each of whom is part of an entrepreneurial culture that values integrity, customer focus, teamwork, and performance. Par’s seasoned management team provides leadership and brings a unique focus to a complex and challenging marketplace. An agile organization enables Par to move decisively and positions management to solve problems intelligently and creatively. In creating a climate that encourages collaboration, Par has become the partner of choice within its industry and has built a diverse network of strategic partnerships with dozens of companies. Through Par, we offer a line of high barrier-to-entry generic drugs, while Strativa provides niche, innovative specialty pharmaceuticals. Spring Valley, Irvine, Par Formulations, Par Sterile Products, Strativa and Business Development are the business units that will serve as catalysts for Par’s continued growth.

Two Divisions, One Shared Vision
Through its demonstrated talent for intelligent product selection, Par has built one of the most promising new product pipelines in the generic drug industry, with more than 90 products awaiting FDA approval, including almost 30 first-to-files, and more than 100 other products in development. Par’s investment in internal product development has been complemented by the efforts of its Business Development team. As we seek to build a stronger company with greater scale and broader scope, Par’s Business Development group will continue to play an important role. To become a well-rounded and fully-integrated generic and specialty pharmaceutical company with long-term, sustainable growth, Par will continue to pursue attractive acquisition opportunities. We envision an expanded Par, with new technologies and capabilities, and a broadened product portfolio with additional dosage forms. By executing on this strategic vision, we will become the company we aspire to be, meet the needs of patients and create true value for all the investors who have put their trust in us.